|
|
|
Insider
Information: |
Mott David M |
Relationship: |
Director |
City: |
Gaithersburg |
State: |
MD |
|
|
Insider
Summary: |
|
|
|
Companies Owned : |
36 |
|
Direct
Shares |
6,113,369 |
|
Indirect Shares
|
266,283,930 |
|
|
Direct
Value |
$8,965,725 |
|
|
Indirect Value
|
$986,970,198 |
|
|
Total
Shares |
272,397,299 |
|
|
Total
Value |
$995,935,923 |
|
|
|
|
|
|
|
|
Historical
Performance :
Based on 6 Month Return Percentages |
Buys
|
Sells
|
Total
Filings :
|
10
|
0
|
Stock
price went up :
|
4
|
0
|
Stock
price went down : |
6
|
0
|
|
|
|
Gain/Loss Ratio : |
0.0
|
0.0
|
Percentage
Gain/Loss : |
23.6%
|
0.0%
|
|
|
|
|
|
|
Holdings
:
Menu |
Company Name |
Ticker |
Relation |
Direct Date |
Direct Shares |
Indirect Date |
Indirect Shares |
Total Value Sold |
|
Medimmune Inc |
MEDI |
Vice Chairman, CEO & P... |
2007-06-01 |
0 |
2003-09-15 |
0 |
Premium* |
|
Clovis Oncology, Inc. |
CLVS |
10% Owner |
2011-11-21 |
0 |
2013-06-03 |
575 |
Premium* |
|
Millennial Media Inc |
MM |
10% Owner |
2012-04-03 |
0 |
2012-10-29 |
8,196,614 |
Premium* |
|
Tesaro, Inc. |
TSRO |
Director, 10% Owner |
2019-01-22 |
0 |
2019-01-22 |
0 |
Premium* |
|
Workday, Inc. |
WDAY |
10% Owner |
2013-04-09 |
0 |
2013-04-09 |
1,171 |
Premium* |
|
Interleukin Genetics Inc |
ILIU |
10% Owner |
|
0 |
2016-07-29 |
55,418,811 |
Premium* |
|
Epizyme, Inc. |
EPZM |
Director |
2022-08-12 |
0 |
2022-08-12 |
0 |
Premium* |
|
Care.com Inc |
CRCM |
10% Owner |
2014-01-29 |
0 |
2017-11-06 |
2,302 |
Premium* |
|
Roka Bioscience, Inc. |
ROKA |
10% Owner |
|
0 |
2014-07-22 |
3,216,810 |
Premium* |
|
Loxo Oncology, Inc. |
LOXO |
10% Owner |
2014-08-06 |
0 |
2014-08-06 |
1,789,420 |
Premium* |
|
Box Inc |
BOX |
10% Owner |
|
0 |
2015-01-28 |
0 |
Premium* |
|
Tracon Pharmaceuticals, Inc. |
TCON |
10% Owner |
2015-02-04 |
0 |
2016-11-29 |
2,758,039 |
Premium* |
|
Champions Biotechnology Inc |
CSBR |
10% Owner |
|
0 |
2015-03-11 |
18,750,000 |
Premium* |
|
Ardelyx Inc |
ARDX |
Director |
2023-06-15 |
1,192,275 |
2019-12-09 |
6,564,372 |
Premium* |
|
Nuvelo Inc |
ABIO |
10% Owner |
|
0 |
2018-02-26 |
0 |
Premium* |
|
Synlogic Inc |
SYBX |
10% Owner |
2015-10-05 |
0 |
2018-01-26 |
4,228,940 |
Premium* |
|
Avalo Therapeutics, Inc |
AVTX |
10% Owner |
2015-10-20 |
0 |
2015-10-20 |
594,245 |
Premium* |
|
Adaptimmune Therapeutics PLC |
ADAP |
Director, 10% Owner |
|
0 |
2020-01-24 |
102,478,668 |
Premium* |
|
Aveo Pharmaceuticals Inc |
AVEO |
10% Owner |
|
0 |
2019-04-08 |
25,243,865 |
Premium* |
|
Achaogen Inc |
AKAO |
10% Owner |
|
0 |
2016-12-19 |
5,215,128 |
Premium* |
|
Ra Pharmaceuticals, Inc. |
RARX |
10% Owner |
2016-10-31 |
0 |
2016-10-31 |
3,490,073 |
Premium* |
|
Cascadian Therapeutics, Inc |
CASC |
10% Owner |
|
0 |
2018-03-09 |
0 |
Premium* |
|
Mulesoft, Inc |
MULE |
10% Owner |
|
0 |
2018-05-01 |
0 |
Premium* |
|
Mersana Therapeutics, Inc. |
MRSN |
Director |
2024-01-02 |
588,694 |
2024-01-02 |
9,595 |
Premium* |
|
Regulus Therapeutics Inc. |
RGLS |
10% Owner |
|
0 |
2019-05-07 |
2,052,454 |
Premium* |
|
Surface Oncology, Inc. |
SURF |
10% Owner |
2018-04-23 |
0 |
2018-04-23 |
3,312,877 |
Premium* |
|
Rhythm Pharmaceuticals, Inc. |
RYTM |
10% Owner |
2017-10-10 |
0 |
2017-10-10 |
4,909,956 |
Premium* |
|
Appian Corp |
APPN |
10% Owner |
2017-11-20 |
0 |
2018-02-13 |
2,031 |
Premium* |
|
Elastic N.v. |
ESTC |
10% Owner |
2018-10-10 |
0 |
2018-10-10 |
2,197,503 |
Premium* |
|
Genocea Biosciences, Inc. |
GNCA |
10% Owner |
2019-02-14 |
0 |
2019-06-24 |
7,225,676 |
Premium* |
|
Trevi Therapeutics, Inc. |
TRVI |
10% Owner |
2019-05-09 |
0 |
2019-05-09 |
4,438,562 |
Premium* |
|
Nightstar Therapeutics Plc |
NITE |
Director, 10% Owner |
2019-06-07 |
0 |
2019-06-07 |
0 |
Premium* |
|
Mirum Pharmaceuticals, Inc. |
MIRM |
10% Owner |
2019-07-22 |
0 |
2019-07-22 |
4,186,243 |
Premium* |
|
Cloudflare, Inc. |
NET |
10% Owner |
2019-09-17 |
4,059,376 |
2019-09-17 |
0 |
Premium* |
|
Novavax Inc |
NVAX |
Director |
2023-06-10 |
43,800 |
|
0 |
Premium* |
|
Enliven Therapeutics Ord Shs |
ELVN |
Director |
2022-02-23 |
229,224 |
2022-02-10 |
0 |
Premium* |
|
|
|
|
|
|
|
|
|
|
Records found :
221 |
Free Registration Required For Full Results. Limit: 25
|
|
Download |
Page 3 of 9
|
Ticker |
Company Name |
Relation |
Off-Dir-10% |
Trans. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
EPZM |
Epizyme, Inc. |
Director |
|
2019-06-30 |
4 |
A |
$12.55 |
$23,443 |
D/D |
1,868 |
15,847 |
0 |
- |
|
EPZM |
Epizyme, Inc. |
Director |
|
2019-09-30 |
4 |
A |
$10.32 |
$23,437 |
D/D |
2,271 |
18,118 |
0 |
- |
|
EPZM |
Epizyme, Inc. |
Director |
|
2019-12-31 |
4 |
A |
$24.60 |
$23,419 |
D/D |
952 |
19,070 |
0 |
- |
|
EPZM |
Epizyme, Inc. |
Director |
|
2020-03-31 |
4 |
A |
$15.51 |
$23,451 |
D/D |
1,512 |
20,582 |
0 |
- |
|
ELVN |
Enliven Therapeutics Ord ... |
Director |
|
2022-02-11 |
4 |
B |
$1.23 |
$17,925 |
D/D |
14,573 |
23,326 |
2.39 |
- |
|
ELVN |
Enliven Therapeutics Ord ... |
Director |
|
2022-02-14 |
4 |
B |
$1.18 |
$10,030 |
D/D |
8,500 |
31,826 |
2.39 |
- |
|
ARDX |
Ardelyx Inc |
Director |
|
2017-06-07 |
4 |
A |
$0.00 |
$0 |
D/D |
19,534 |
33,877 |
0 |
- |
|
NVAX |
Novavax Inc |
Director |
|
2021-09-23 |
4 |
S |
$251.32 |
$6,312,616 |
D/D |
(24,961) |
40,000 |
0 |
- |
|
NVAX |
Novavax Inc |
Director |
|
2022-06-17 |
4 |
OE |
$0.00 |
$0 |
D/D |
700 |
40,700 |
0 |
- |
|
NVAX |
Novavax Inc |
Director |
|
2023-06-10 |
4 |
OE |
$0.00 |
$0 |
D/D |
3,100 |
43,800 |
0 |
- |
|
ELVN |
Enliven Therapeutics Ord ... |
Director |
|
2022-02-15 |
4 |
B |
$1.20 |
$23,462 |
D/D |
19,552 |
51,378 |
2.39 |
- |
|
EPZM |
Epizyme, Inc. |
Director |
|
2019-06-26 |
4 |
S |
$12.85 |
$674,176 |
I/I |
(52,472) |
52,473 |
0 |
- |
|
ARDX |
Ardelyx Inc |
Director |
|
2018-06-13 |
4 |
A |
$0.00 |
$0 |
D/D |
20,843 |
54,720 |
0 |
- |
|
ELVN |
Enliven Therapeutics Ord ... |
Director |
|
2022-02-16 |
4 |
B |
$1.20 |
$14,135 |
D/D |
11,779 |
63,157 |
2.39 |
- |
|
NVAX |
Novavax Inc |
Director |
|
2020-06-16 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
64,961 |
|
- |
|
ELVN |
Enliven Therapeutics Ord ... |
Director |
|
2022-02-17 |
4 |
B |
$1.17 |
$17,076 |
D/D |
14,595 |
77,752 |
2.39 |
- |
|
RARX |
Ra Pharmaceuticals, Inc. |
10% Owner |
|
2016-10-31 |
4 |
S |
$13.00 |
$5,655 |
I/I |
(435) |
80,223 |
0 |
- |
|
RARX |
Ra Pharmaceuticals, Inc. |
10% Owner |
|
2016-10-31 |
4 |
OE |
$0.07 |
$5,646 |
I/I |
80,658 |
80,658 |
0 |
- |
|
EPZM |
Epizyme, Inc. |
Director |
|
2020-06-26 |
4 |
B |
$16.03 |
$994,165 |
D/D |
62,019 |
82,601 |
2.39 |
% |
|
EPZM |
Epizyme, Inc. |
Director |
|
2020-06-30 |
4 |
A |
$16.06 |
$23,432 |
D/D |
1,459 |
84,060 |
0 |
- |
|
EPZM |
Epizyme, Inc. |
Director |
|
2020-09-30 |
4 |
A |
$11.93 |
$23,442 |
D/D |
1,965 |
86,025 |
0 |
- |
|
ARDX |
Ardelyx Inc |
Director |
|
2019-06-13 |
4 |
A |
$0.00 |
$0 |
D/D |
32,846 |
87,566 |
0 |
- |
|
EPZM |
Epizyme, Inc. |
Director |
|
2020-12-31 |
4 |
A |
$10.86 |
$23,436 |
D/D |
2,158 |
88,183 |
0 |
- |
|
ARDX |
Ardelyx Inc |
Director |
|
2020-06-09 |
4 |
A |
$0.00 |
$0 |
D/D |
12,995 |
100,561 |
0 |
- |
|
ARDX |
Ardelyx Inc |
Director |
|
2020-06-10 |
4 |
A |
$0.00 |
$0 |
D/D |
1,079 |
101,640 |
0 |
- |
|
221 Records found
|
|
Page 3 of 9 |
|
Free Registration Required For Full Results. Limit: 25
|
|
|
Transaction Code Key: |
Ownership Code Key |
|
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
|
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Aquired |
|
IO |
- Initital Ownership |
D |
- Disposed |
|
|
|
|
|
|